insitro valuation, funding and investors

insitro works in machine learning-driven drug discovery, based in South San Francisco, United States. Founded in 2018, it has about 257 employees.

Biotechnology Series C

VALUATION · TODAY

$1.13B −10% after Series C

Range $195M – $5.76B · Grade D

TODAY

+12 MO

$2.00B

$4.00B

$6.00B

$8.00B

2019

2020

2021

2022

2023

2024

2025

2026

2027

Series B $143M

Series C $400M

ValuationBefore first round12-month outlook: where it points, how wide it fansHover the past: the outlook shows what was predicted then

HEADCOUNT · TODAY257 employees

+4%6m growth

−6%1y growth

−20%2y growth

200

400

Data from Jan 2021

TODAY

Predicted in 1 yr $1.01B −10% vs today

Predicted next raise $497M if a round comes

Winding-down probability 59%

Last round: Series C · $400M · Mar 2021
Valuation at last round: $2.65B · implied
Headcount: 257 · flat
Grade: D
Founded: 2018

How VCMC values companies →

insitro valuation today

VCMC values insitro at $1.1B today, with a range of $195M to $5.8B and a grade of D. The valuation starts from its last funding round, a Series C round in Mar 2021.

Valuation by date (109 rows)

Each point is what the model would have shown on that date, using only what was known then; before its first round, a company is valued as a startup because it later raised.

insitro: valuation by date, as the model would have shown it on each date
Date	Valuation	Range	Predicted in 1 yr	Phase	Headcount	Trend	Grade	Winding-down probability
1 Jan 2018	$9.05M	$3.29M – $24.9M	$12.4M (+37%)	before first round	–	unknown	D	0%
1 Feb 2018	$9.29M	$3.38M – $25.5M	$12.7M (+37%)	before first round	–	unknown	D	0%
1 Mar 2018	$9.52M	$3.47M – $26.2M	$13.1M (+37%)	before first round	–	unknown	D	0%
1 Apr 2018	$9.78M	$3.56M – $26.9M	$13.4M (+37%)	before first round	–	unknown	D	0%
1 May 2018	$10.0M	$3.65M – $27.6M	$13.8M (+37%)	before first round	–	unknown	D	0%
1 Jun 2018	$10.3M	$3.75M – $28.3M	$14.1M (+37%)	before first round	–	unknown	D	0%
1 Jul 2018	$10.6M	$3.85M – $29.1M	$14.5M (+37%)	before first round	–	unknown	D	0%
1 Aug 2018	$10.9M	$3.96M – $29.9M	$14.7M (+35%)	before first round	–	unknown	D	0%
1 Sep 2018	$11.2M	$4.06M – $30.7M	$14.8M (+32%)	before first round	–	unknown	D	0%
1 Oct 2018	$11.5M	$4.17M – $31.5M	$14.9M (+30%)	before first round	–	unknown	D	0%
1 Nov 2018	$11.8M	$4.28M – $32.3M	$15.1M (+28%)	before first round	–	unknown	D	0%
1 Dec 2018	$12.1M	$4.40M – $33.2M	$15.2M (+26%)	before first round	–	unknown	D	0%
1 Jan 2019	$12.4M	$4.52M – $34.1M	$15.3M (+24%)	before first round	–	unknown	D	0%
1 Feb 2019	$12.7M	$4.64M – $35.0M	$15.5M (+21%)	before first round	–	unknown	D	0%
1 Mar 2019	$13.1M	$4.75M – $35.9M	$15.6M (+19%)	before first round	–	unknown	D	0%
1 Apr 2019	$13.4M	$4.88M – $36.8M	$15.7M (+17%)	before first round	–	unknown	D	0%
1 May 2019	$13.8M	$5.01M – $37.8M	$15.9M (+15%)	before first round	–	unknown	D	0%
1 Jun 2019	$14.1M	$5.15M – $38.8M	$16.0M (+13%)	before first round	–	unknown	D	0%
1 Jul 2019	$14.5M	$5.28M – $39.8M	$16.2M (+11%)	before first round	–	unknown	D	0%
1 Aug 2019	$14.7M	$5.33M – $40.2M	$16.3M (+11%)	before first round	–	unknown	D	0%
1 Sep 2019	$14.8M	$5.38M – $40.6M	$16.5M (+11%)	before first round	–	unknown	D	0%
1 Oct 2019	$14.9M	$5.43M – $41.0M	$16.6M (+11%)	before first round	–	unknown	D	0%
1 Nov 2019	$15.1M	$5.48M – $41.4M	$16.8M (+11%)	before first round	–	unknown	D	0%
1 Dec 2019	$15.2M	$5.53M – $41.7M	$16.9M (+11%)	before first round	–	unknown	D	0%
1 Jan 2020	$15.3M	$5.58M – $42.1M	$17.1M (+11%)	before first round	–	unknown	D	0%
1 Feb 2020	$15.5M	$5.63M – $42.5M	$17.2M (+11%)	before first round	–	unknown	D	0%
1 Mar 2020	$15.6M	$5.68M – $42.9M	$17.4M (+11%)	before first round	–	unknown	D	0%
1 Apr 2020	$15.7M	$5.73M – $43.3M	$17.5M (+11%)	before first round	–	unknown	D	0%
1 May 2020	$15.9M	$5.78M – $43.6M	$17.7M (+11%)	before first round	–	unknown	D	0%
27 May 2020	$1.0B	$671M – $2.3B	$1.5B (+50%)	after a round	–	unknown	C	0%
1 Jun 2020	$1.0B	$671M – $2.3B	$1.5B (+49%)	after a round	–	unknown	C	0%
1 Jul 2020	$1.1B	$671M – $2.3B	$1.5B (+44%)	after a round	–	unknown	C	0%
1 Aug 2020	$1.1B	$671M – $2.3B	$1.5B (+39%)	after a round	–	unknown	C	0%
1 Sep 2020	$1.1B	$671M – $2.3B	$1.5B (+35%)	after a round	–	unknown	C	0%
1 Oct 2020	$1.2B	$671M – $2.3B	$1.5B (+30%)	after a round	–	unknown	C	0%
1 Nov 2020	$1.2B	$671M – $2.3B	$1.5B (+26%)	after a round	–	unknown	C	0%
1 Dec 2020	$1.3B	$671M – $2.3B	$1.5B (+22%)	after a round	–	unknown	C	0%
1 Jan 2021	$1.3B	$671M – $2.3B	$1.5B (+17%)	after a round	75	unknown	C	0%
1 Feb 2021	$1.3B	$671M – $2.3B	$1.5B (+14%)	after a round	75	unknown	C	0%
1 Mar 2021	$1.4B	$671M – $2.3B	$1.5B (+10%)	after a round	75	unknown	C	0%
16 Mar 2021	$2.7B	$1.9B – $4.9B	$3.4B (+30%)	after a round	75	unknown	B	0%
1 Apr 2021	$2.7B	$1.9B – $4.9B	$3.4B (+28%)	after a round	75	flat	B	0%
1 May 2021	$2.7B	$1.9B – $4.9B	$3.4B (+26%)	after a round	75	flat	B	0%
1 Jun 2021	$2.8B	$1.9B – $4.9B	$3.4B (+23%)	after a round	75	flat	B	0%
1 Jul 2021	$2.9B	$1.9B – $4.9B	$3.4B (+20%)	after a round	75	flat	B	0%
1 Aug 2021	$2.9B	$1.9B – $4.9B	$3.4B (+18%)	after a round	75	flat	B	0%
1 Sep 2021	$3.0B	$1.9B – $4.9B	$3.4B (+15%)	after a round	75	flat	B	0%
1 Oct 2021	$3.1B	$1.9B – $4.9B	$3.4B (+13%)	after a round	75	flat	B	0%
1 Nov 2021	$3.1B	$1.9B – $4.9B	$3.4B (+10%)	after a round	75	flat	B	0%
1 Dec 2021	$3.2B	$1.9B – $4.9B	$3.4B (+8%)	after a round	75	flat	B	0%
1 Jan 2022	$3.3B	$1.9B – $4.9B	$3.4B (+5%)	after a round	75	flat	B	0%
1 Feb 2022	$3.9B	$2.2B – $5.9B	$4.1B (+5%)	after a round	170	growing	B	0%
1 Mar 2022	$4.1B	$2.2B – $5.9B	$4.1B (+2%)	after a round	170	growing	B	0%
1 Apr 2022	$4.1B	$2.2B – $5.9B	$4.1B (0%)	after a round	170	growing	B	0%
1 May 2022	$4.1B	$2.3B – $5.9B	$4.1B (0%)	after a round	170	growing	B	0%
1 Jun 2022	$4.1B	$2.3B – $5.9B	$4.1B (0%)	after a round	170	growing	B	0%
1 Jul 2022	$4.1B	$2.3B – $5.9B	$4.1B (0%)	after a round	170	growing	B	0%
1 Aug 2022	$4.1B	$2.3B – $5.9B	$4.1B (0%)	after a round	170	growing	B	0%
1 Sep 2022	$4.1B	$2.3B – $5.9B	$4.1B (0%)	after a round	170	growing	B	0%
1 Oct 2022	$4.1B	$2.3B – $5.9B	$4.1B (0%)	after a round	170	growing	B	0%
1 Nov 2022	$4.1B	$1.6B – $5.9B	$4.1B (0%)	after a round	170	unknown	C	0%
1 Dec 2022	$4.1B	$1.5B – $5.9B	$4.1B (0%)	after a round	170	unknown	C	0%
1 Jan 2023	$4.4B	$2.1B – $6.2B	$4.4B (0%)	after a round	220	up	B	0%
1 Feb 2023	$4.4B	$2.1B – $6.2B	$4.4B (0%)	after a round	220	up	B	0%
1 Mar 2023	$4.4B	$2.1B – $6.2B	$4.4B (0%)	after a round	220	up	B	0%
1 Apr 2023	$4.4B	$1.9B – $6.2B	$4.4B (0%)	after a round	220	up	B	0%
1 May 2023	$4.4B	$1.8B – $6.2B	$4.4B (0%)	after a round	220	up	C	0%
1 Jun 2023	$4.4B	$1.8B – $6.2B	$4.4B (0%)	after a round	220	up	C	0%
1 Jul 2023	$4.4B	$1.8B – $6.2B	$4.3B (0%)	after a round	220	up	C	0%
1 Aug 2023	$4.4B	$1.7B – $6.2B	$4.3B (-1%)	after a round	220	up	C	0%
1 Sep 2023	$4.4B	$983M – $6.2B	$4.4B (0%)	after a round	220	unknown	C	0%
1 Oct 2023	$4.6B	$1.8B – $6.5B	$4.5B (-2%)	after a round	270	up	C	0%
1 Nov 2023	$4.6B	$1.7B – $6.5B	$4.5B (-2%)	after a round	270	up	C	0%
1 Dec 2023	$4.6B	$1.7B – $6.5B	$4.5B (-2%)	after a round	270	up	C	0%
1 Jan 2024	$4.6B	$1.7B – $6.5B	$4.5B (-3%)	after a round	270	up	C	0%
1 Feb 2024	$4.6B	$1.6B – $6.5B	$4.4B (-3%)	after a round	270	up	C	0%
1 Mar 2024	$4.6B	$1.6B – $6.5B	$4.5B (-2%)	after a round	280	up	C	0%
1 Apr 2024	$4.6B	$1.2B – $6.5B	$4.5B (-2%)	after a round	280	up	C	0%
1 May 2024	$4.6B	$1.2B – $6.5B	$4.5B (-2%)	after a round	280	up	C	0%
1 Jun 2024	$4.6B	$1.2B – $6.5B	$4.5B (-2%)	after a round	280	up	C	0%
1 Jul 2024	$4.7B	$2.2B – $6.7B	$4.7B (0%)	after a round	320	growing	B	0%
1 Aug 2024	$4.7B	$1.1B – $6.6B	$4.5B (-4%)	after a round	320	up	C	0%
1 Sep 2024	$4.7B	$1.1B – $6.6B	$4.5B (-4%)	after a round	320	up	C	0%
1 Oct 2024	$4.6B	$1.1B – $6.6B	$4.5B (-4%)	after a round	320	up	C	0%
1 Nov 2024	$4.7B	$1.0B – $6.7B	$4.6B (-2%)	after a round	330	up	C	0%
1 Dec 2024	$4.7B	$996M – $6.7B	$4.6B (-2%)	after a round	330	up	C	0%
1 Jan 2025	$4.7B	$964M – $6.6B	$4.6B (-2%)	after a round	330	up	C	0%
1 Feb 2025	$4.7B	$933M – $6.6B	$4.6B (-2%)	after a round	330	up	C	0%
1 Mar 2025	$4.7B	$906M – $6.6B	$4.5B (-2%)	after a round	330	up	C	0%
1 Apr 2025	$4.6B	$721M – $6.6B	$4.5B (-2%)	after a round	330	up	D	0%
1 May 2025	$4.5B	$696M – $6.4B	$4.3B (-4%)	after a round	330	up	D	0%
1 Jun 2025	$4.5B	$670M – $6.4B	$4.3B (-4%)	after a round	330	up	D	0%
1 Jul 2025	$2.9B	$345M – $5.9B	$2.5B (-12%)	after a round	277	flat	D	24%
1 Aug 2025	$1.9B	$326M – $6.1B	$1.6B (-14%)	after a round	272	flat	D	51%
1 Sep 2025	$1.8B	$310M – $6.0B	$1.6B (-12%)	after a round	272	flat	D	51%
1 Oct 2025	$1.0B	$295M – $6.4B	$894M (-11%)	after a round	272	down	D	90%
1 Nov 2025	$865M	$279M – $6.4B	$793M (-8%)	after a round	266	down	D	97%
1 Dec 2025	$836M	$266M – $6.4B	$793M (-5%)	after a round	266	down	D	97%
1 Jan 2026	$808M	$252M – $6.4B	$793M (-2%)	after a round	266	down	D	97%
1 Feb 2026	$795M	$247M – $6.4B	$793M (0%)	after a round	266	down	D	97%
1 Mar 2026	$795M	$247M – $6.4B	$793M (0%)	after a round	266	down	D	97%
1 Apr 2026	$782M	$243M – $6.3B	$638M (-18%)	after a round	248	down	D	97%
1 May 2026	$782M	$243M – $6.3B	$638M (-18%)	after a round	248	down	D	97%
1 Jun 2026	$883M	$243M – $6.2B	$731M (-17%)	after a round	248	down	D	89%
1 Jul 2026	$987M	$243M – $6.1B	$827M (-16%)	after a round	248	down	D	82%
1 Aug 2026	$1.1B	$245M – $6.0B	$934M (-15%)	after a round	257	flat	D	76%
1 Sep 2026	$1.2B	$245M – $5.9B	$1.0B (-14%)	after a round	257	flat	D	70%
1 Oct 2026	$1.3B	$245M – $5.8B	$1.1B (-13%)	after a round	257	flat	D	64%
24 Oct 2026	$1.1B	$195M – $5.8B	$1.0B (-10%)	after a round	257	flat	D	59%

Key facts about insitro

Founded: 2018
Headquarters: South San Francisco, United States
Employees: about 257 -6% in a year
Total raised: $543M
Funding rounds: 2
Last round: Series C Mar 2021

insitro was founded in 2018 by Daphne Koller.

insitro funding history

insitro has 2 funding rounds on record, from May 2020 to Mar 2021, $543M in total. None disclosed a valuation.

Series C 15 Mar 2021
Led by Canada Pension Plan Investment Board; with Andreessen Horowitz, T. Rowe Price Associates, Casdin Capital, BlackRock, ARCH Venture Partners, Foresite Capital, GV, Third Rock Ventures, Two Sigma Ventures, HOF Capital, Alexandria Venture Investments, Temasek, SoftBank Vision Fund.
Sources: fiercebiotech.com, insitro.com, fiercebiotech.com and 1 more
$400M
Series B 26 May 2020
Led by Andreessen Horowitz; with Canada Pension Plan Investment Board, T. Rowe Price, ARCH Venture Partners, Foresite Capital, Third Rock Ventures, Two Sigma Ventures, BlackRock, Casdin Capital, HOF Capital, GV, WuXi AppTec's Corporate Venture Fund.
Sources: foresitecapital.com, drugdiscoverytrends.com
$143M

insitro investors

16 investors have backed insitro; Andreessen Horowitz and Canada Pension Plan Investment Board led at least one round.

Andreessen Horowitz lead, 2 rounds
Canada Pension Plan Investment Board lead, 2 rounds
ARCH Venture Partners 2 rounds
BlackRock 2 rounds
GV 2 rounds
Two Sigma Ventures 2 rounds
Alexandria Venture Investments
SoftBank Vision Fund
T. Rowe Price
T. Rowe Price Associates
Temasek
WuXi AppTec's Corporate Venture Fund

What insitro does

insitro works in biotechnology, with 10 recorded offerings and customers in healthcare and pharmaceuticals.

Insitro, Inc. is an American biotechnology company engaged in drug discovery and development, with a focus on leveraging machine learning and data integration to decode complex biological systems. The company operates a machine learning platform that combines in vitro cellular data with human clinical data to identify therapeutic insights and interventions in areas such as metabolism, oncology, and neuroscience. insitro also manages a pipeline of wholly-owned and partnered therapeutic programs and provides services to support clinical trials and drug development.

Description from Veridion's company data.

Products and services

Machine Learning-Driven Drug Discovery
Biological System Analysis and Modeling
In Vitro Cellular Data Integration
Clinical Data Integration and Analysis
Therapeutic Insight Generation
Target and Drug Candidate Identification
Clinical Trial Acceleration Solutions
Modular Platform Development and Expansion
Data-Driven Drug Derisking Services
Therapeutic Intervention Delivery Solutions

Markets

Healthcare
Pharmaceuticals

Technology

Machine Learning-Based Therapeutic Insights
Integrated In Vitro Cellular Data with Human Clinical Data
Modular Technology Stack for Iterative Drug Discovery
Unified Data Architecture for Disease Indication Expansion

Business model

Business-to-Business
Manufacturing
Enterprise

Industry codes (NAICS)

541714 Research and Development in Biotechnology (except Nanobiotechnology) 100% match

Questions about insitro

What is insitro worth?

Valuation $1.1B (range $195M to $5.8B), as of 24 Oct 2026.

Has insitro raised money?

insitro has 2 funding rounds on record, from May 2020 to Mar 2021, $543M in total. None disclosed a valuation.

Who has invested in insitro?

Andreessen Horowitz, Canada Pension Plan Investment Board, ARCH Venture Partners, BlackRock, Casdin Capital and Foresite Capital, and 10 more. Lead investors include Andreessen Horowitz and Canada Pension Plan Investment Board.

How many people work at insitro?

About 257, down 6% over the last year. Headcount rose from 75 in Jan 2021 to 330 in Nov 2024, then fell to 257 in Sep 2026.

What does insitro do?

insitro works in biotechnology, with 10 recorded offerings and customers in healthcare and pharmaceuticals. Its main offerings are machine learning-driven drug discovery, biological system analysis and modeling and in vitro cellular data integration.

When was insitro founded, and where is it based?

insitro was founded in 2018 and is based in South San Francisco, United States. It has about 257 employees, down 6% over the last year.

How we value companies Report an issue